Biggest News Aggregation in the World
📰 Beigene News

Page 8 - Beigene News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.

Lai Wang Sells 1,108 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) insider Lai Wang sold 1,108 shares of the business’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $181.92, for a total value of $201,567.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can […]
United States Lai Wang Driehaus Capital Management Colony Group Morgan Stanley Tang Capital Management

Insider Selling: BeiGene, Ltd. (NASDAQ:BGNE) Major Shareholder Sells 273,728 Shares of Stock

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) major shareholder Advisors Ltd. Hhlr sold 273,728 shares of the firm’s stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $207.72, for a total transaction of $56,858,780.16. Following the completion of the sale, the insider now directly owns 142,888,241 shares of […]
United States Xiao Dong Wang Johnv Oyler Xy Capital Ltd Morgan Stanley Colony Group

Advisors Ltd. Hhlr Sells 273,728 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) major shareholder Advisors Ltd. Hhlr sold 273,728 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $207.72, for a total transaction of $56,858,780.16. Following the sale, the insider now owns 142,888,241 shares in the company, […]
United States Xiao Dong Wang Zurcher Kantonalbank Zurich Cantonalbank Johnv Oyler Columbus Asset Advisors Advisors Ltd
Source: wkrb13.com

AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent

BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics patent issued on June 13, 2023. Pharmacyclics is an AbbVie Inc (NYSE: ABBV) company. As per a Bloomberg Law report, AbbVie filed a lawsuit against the China-based company alleging a patent violation related to Brukinsa. "BeiGene's work is original, and we will vigorously defend against all allegation...
Janssen Biotech Inc Beigene Ltd Abbvie Inc Bloomberg Law Benzinga Pro Abbvie Says Beigene
Source: yahoo.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

BGNE INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BeiGene, Ltd. resulting from allegations that BeiGene... | June 15, 2023
United States Phillip Kim Laurence Rosen Chinese Company Securities Class Action Services Drug Administration

BeiGene, Ltd. (NASDAQ:BGNE) COO Sells $739,586.43 in Stock

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) COO Xiaobin Wu sold 3,291 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $224.73, for a total transaction of $739,586.43. The sale was disclosed in a legal filing with the SEC, which can be […]
United States Johnv Oyler Xiaobin Wu Xiao Dong Wang Morgan Stanley Beigene Ltd

BeiGene, Ltd. (NASDAQ:BGNE) Given Consensus Rating of "Moderate Buy" by Brokerages

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) has received an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokerages that […]
United States Johnv Oyler Xiaodong Wang Xiao Dong Wang Xiaobin Wu Beigene Ltd
Source: wkrb13.com

BeiGene (NASDAQ:BGNE) Trading Down 3.1%

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating)’s stock price traded down 3.1% on Tuesday . The stock traded as low as $212.34 and last traded at $215.03. 16,488 shares were traded during mid-day trading, a decline of 92% from the average session volume of 212,068 shares. The stock had previously closed at $221.84. Analyst Ratings Changes […]
United States Xiao Dong Wang Xiaobin Wu Johnv Oyler Xiaodong Wang Morgan Stanley

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science